Sarcoma  >>  oxaliplatin 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
2009-017437-22: MANAGEMENT OF PRIMARY AND SECUNDARY PERITONEAL CARCINOMATOSIS FROM COLO-RECTAL CANCER, RECURRENT OVARIAN CANCER AND ABDOMINAL SARCOMATOSIS BY CYTOREDUCTIVE SURGERY PLUS HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY

Ongoing
2
60
Europe
Solvent for parenteral use, Solution for injection, CISPLATINO TEVA*EV 50MG 100ML, ADRIBLASTINA*EV FL 10MG+F 5ML, MITOMYCIN C, ELOXATIN*INFUS 1FL 10ML 5MG/ML
AZIENDA OSPEDALIERA DI PERUGIA
Peritoneal carcinomatosis
 
 
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Not yet recruiting
2
120
Europe
Dostarlimab, Chemotherapy
UNICANCER, National Cancer Institute, France, GlaxoSmithKline
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
10/28
09/30
CodeBreak101, NCT04185883: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
12/26
12/27

Download Options